Page 55 - TD-3-4

Tumor Discovery PPAR agonist and cancer

doi: 10.1016/j.crphar.2022.100110 37. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The
peroxisome proliferator-activated receptor: A family of
26. Rathaur P, Soni MN, Gelat B, Rawal R, Pandya HA, Johar K.
Network pharmacology-based evaluation of natural nuclear receptors role in various diseases. J Adv Pharm
compounds with paclitaxel for the treatment of metastatic Technol Res. 2011;2(4):236-240.
breast cancer. Toxicol Appl Pharmacol. 2021;423:115576. doi: 10.4103/2231-4040.90879
doi: 10.1016/j.taap.2021.115576 38. Tan Y, Wang M, Yang K, Chi T, Liao Z, Wei P. PPAR-α
modulators as current and potential cancer treatments.
27. Rodrigues R, Duarte D, Vale N. Drug repurposing in cancer
therapy: Influence of patient’s genetic background in breast Front Oncol. 2021;11:599995.
cancer treatment. Int J Mol Sci. 2022;23(8):4280. doi: 10.3389/fonc.2021.599995
doi: 10.3390/ijms23084280 39. Chi T, Wang M, Wang X, et al. PPAR-γ modulators as
current and potential cancer treatments. Front Oncol.
28. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug
repositioning: A brief overview. J Pharm Pharmacol. 2021;11:737776.
2020;72(9):1145-1151. doi: 10.3389/fonc.2021.737776
doi: 10.1111/jphp.13273 40. Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS.
Exploration and development of PPAR modulators in health
29. Oprea TI, Mestres J. Drug repurposing: Far beyond new
targets for old drugs. AAPS J. 2012;14(4):759-763. and disease: An update of clinical evidence. Int J Mol Sci.
2019;20(20):5055.
doi: 10.1208/s12248-012-9390-1
doi: 10.3390/ijms20205055
30. Patel B, Gelat B, Soni M, Rathaur P, Kaid Johar SR. 41. Kim SY, Kim MS, Lee MK, et al. PPAR-γ induces growth
Bioinformatics perspective of drug repurposing. Curr inhibition and apoptosis through upregulation of insulin-
Bioinform. 2024;19(4):295-315.
like growth factor-binding protein-3 in gastric cancer cells.
doi: 10.2174/0115748936264692230921071504 Braz J Med Biol Res. 2015;48(3):226-233.
31. Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, doi: 10.1590/1414-431X20144212
Murugesan S. Drug repurposing: An effective tool in modern 42. Skelhorne-Gross G, Nicol CJB. The key to unlocking the
drug discovery. Russ J Bioorg Chem. 2023;49(2):157-166.
chemotherapeutic potential of PPAR-γ ligands: Having the
doi: 10.1134/S1068162023020139 right combination. PPAR Res. 2012;2012:946943.
32. Botta M, Audano M, Sahebkar A, Sirtori CR, Mitro N, doi: 10.1155/2012/946943
Ruscica M. PPAR agonists and metabolic syndrome: An 43. Panigrahy D, Kaipainen A, Huang S, et al. PPARα agonist
established role? Int J Mol Sci. 2018;19(4):1197.
fenofibrate suppresses tumor growth through direct and
doi: 10.3390/ijms19041197 indirect angiogenesis inhibition. Proc Natl Acad Sci.
33. Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor 2008;105(3):985-990.
in different diseases and their ligands: Physiological doi: 10.1073/pnas.0711281105
importance and clinical implications. Eur J Med Chem. 44. Rigano D, Sirignano C, Taglialatela-Scafati O. The potential
2019;166:502-513.
of natural products for targeting PPARα. Acta Pharm Sinica
doi: 10.1016/j.ejmech.2019.01.067 B. 2017;7(4):427-438.
34. van Raalte DH, Li M, Pritchard PH, Wasan KM. doi: 10.1016/j.apsb.2017.05.005
Peroxisome proliferator-activated receptor (PPAR)-α:
A pharmacological target with a promising future. Pharm 45. Chiarelli F, Marzio DD. Peroxisome proliferator-activated
receptor-γ agonists and diabetes: Current evidence and future
Res. 2004;21:1531-1538.
perspectives. Vasc Health Risk Manag. 2008;4(2):297-304.
doi: 10.1023/b: pham.0000041444.06122.8d
doi: 10.2147/vhrm.s993
35. Corrales P, Vidal-Puig A, Medina-Gómez G. PPARs and 46. Ngoc LP, Man HY, Besselink H, Cam HD, Brouwer A, van
metabolic disorders associated with challenged adipose der Burg B. Identification of PPAR-activating compounds in
tissue plasticity. Int J Mol Sci. 2018;19(7):2124.
herbal and edible plants and fungi from Vietnam. Ind Crops
doi: 10.3390/ijms19072124 Prod. 2019;129:195-200.
36. Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity- doi: 10.1016/j.indcrop.2018.12.003
induced T2DM, dyslipidaemia and NAFLD. Nat Rev 47. Korbecki J, Bobiński R, Dutka M. Self-regulation of the
Endocrinol. 2017;13(1):36-49.
inflammatory response by peroxisome proliferator-activated
doi: 10.1038/nrendo.2016.135. receptors. Inflamm Res. 2019;68:443-458.

Volume 3 Issue 4 (2024) 12 doi: 10.36922/td.4003